Bevacizumab (BEV), a monoclonal antibody against vascular endothelial growth factor (VEGF) that inhibits VEGF signaling, was first approved for patients with metastatic CRC in 2004 [3] and then extensively used in broad types of cancer treatments [4]. The gene discussed is VEGFA; the disease is cancer.